Rotterdam criteria identified 4 polycystic ovary syndrome (PCOS) phenotypes based on the combination of anovulation (ANOV), hyperandrogenism (HA), and polycystic ovaries (PCOs): phenotype 1 (ANOV + HA + PCO), phenotype 2 (ANOV + HA), phenotype 3 (HA + PCO), and phenotype 4 (ANOV + PCO). Anti-Müllerian hormone (AMH) was suggested to play a pathophysiologic and diagnostic role in this syndrome. The aim of this study was to compare AMH levels among the different phenotypes in relation to clinical, endocrine, and metabolic features. We enrolled 117 women with PCOS (body mass index: 25.89 ± 6.20 kg/m2, age range: 18-37 years) and 24 controls. Anthropometric characteristics, hirsutism score, ultrasound ovarian features, and hormonal parameters, including AMH, were evaluated. Each participant also underwent an oral glucose tolerance test and an euglycemic–hyperinsulinemic clamp. The prevalence of phenotypes 1 to 4 was 62.4%, 8.6%, 11.1%, and 17.9%, respectively. Body mass index and insulin resistance indexes were similar among the groups. Phenotype 1 showed the highest luteinizing hormone, androgens levels, ovarian volume, and AMH concentrations (9.27 ± 8.17 ng/mL, P < .05) versus phenotype 2 and controls. Phenotype 2 women were hirsute, showed an intermediate free androgen index value, low ovarian volume, and low AMH levels (4.05 ± 4.12 ng/mL). Phenotype 3 showed an intermediate state of HA and slightly augmented AMH levels (5.87 ± 4.35 ng/mL). The clinical and endocrine characteristics of phenotype 4 resembled those of controls, except for higher ovarian volume and AMH levels (7.62 ± 3.85 ng/mL; P < .05). Our results highlight the heterogeneity of the association between increased AMH levels, menstrual dysfunction, and HA in the different PCOS phenotypes, thus offering a key to an understanding of the current controversy on the value of AMH measurement in PCOS.
FranksS. Polycystic ovary syndrome. N Engl J Med. 1995;333:853–861.
2.
PasqualiRStener-VictorinEYildizBO. PCOS forum: research in polycystic ovary syndrome today and tomorrow. Clin Endocrinol (Oxf). 2011;74(4):424–433.
3.
ZawadskiJKDunaifA. Diagnostic Criteria for Polycystic Ovary Syndrome: Towards A Rational Approach. Polycystic Ovary Syndrome 2011. Boston, MA: Blackwell Scientific; 2011:377–384.
4.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25.
5.
BelosiCSelvaggiLApaR. Is the PCOS diagnosis solved by ESHRE/ASRM 2003 consensus or could it include ultrasound examination of the ovarian stroma?Hum Reprod. 2006;21(12):3108–3115.
6.
BroekmansFJKnauffEAValkenburgOLavenJSEijkemansMJFauserBC. PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG. 2006;113(10):1210–1217.
7.
GeisthövelFRabeT. The ESHRE/ASRM consensus on polycystic ovary syndrome (PCOS)—an extended critical analysis. Reprod Biomed Online. 2007;14(4):522–535.
8.
MarchWAMooreVMWillsonKJPhillipsDINormanRJDaviesMJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010;25(2):544–551.
9.
CarlssonIBScottJEVisserJARitvosOThemmenAPHovattaO. Anti-Mullerian hormone inhibits initiation of growth of human primordial ovarian follicles in vitro. Hum Reprod. 2006;21(9):2223–2227.
10.
NardoLGYatesAPRobertsSAPembertonPLaingI. The relationships between AMH, androgens, insulin resistance and basal ovarian follicular status in non-obese subfertile women with and without polycystic ovary syndrome. 2009;24(11):2917–2923.
11.
PignyPMerlenERobertY. Elevated serum level of anti-Mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab. 2003;88(12):5957–5962.
12.
PellattLRiceSMasonHD. Anti-Müllerian hormone and polycystic ovary syndrome: a mountain too high?Reproduction. 2010;139(5):825–833.
TreloarAEBoyntonREBehnBG. Variation of the human menstrual cycle through reproductive life. Int J Fertil. 1967;12(1 pt 2):77–126.
15.
FerrimanDGallweyJD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961;21:1440–1447.
16.
CiampelliMFulghesuAMCucinelliF. Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome. Metabolism. 1999;48(2):167–172.
17.
De SimoneMVerrottiAIughettiL. Increased visceral adipose tissue is associated with increased circulating insulin and decreased sex hormone binding globulin levels in massively obese adolescent girls. J Endocrinol Invest. 2001;24(6):438–444.
18.
PeterkinBB. Dietary guidelines for Americans. J Am Diet Assoc. 1990;90(12):1725–1727.
19.
FulghesuAMCiampelliMBelosiC. A new ultrasound criterion for the diagnosis of polycystic ovary syndrome: the ovarian stroma/total area ratio. Fertil Steril. 2001;76(2):326–323.
20.
OrsiniLFVenturoliSLorussoR. Ultrasonic findings in polycystic ovarian disease. Fertil Steril. 1985;43(5):709–714.
21.
CiampelliMLeoniFCucinelliF. Assessment of insulin sensitivity from measurements in the fasting state and during an oral glucose tolerance test in polycystic ovary syndrome and menopausal patients. J Clin Endocrinol Metab. 2005;90(3):1398–1406.
22.
DeFronzoRATobinJDAndresR. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237(3):E214–E223.
23.
BroekmansFJFauserBC. Diagnostic criteria for polycystic ovarian syndrome. Endocrine. 2006;30(1):3–11.
24.
WeltCKGudmundssonJAArasonG. Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. J Clin Endocrinol Metab. 2006;91(12):4842–4848.
25.
AzzizRCarminaEDewaillyD. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91(2):456–488.
26.
DewaillyDCatteau-JonardSReyssAC. Oligoanovulation with polycystic ovaries but not overt hyperandrogenism. J Clin Endocrinol Metab. 2006;91(10):3922–3927.
27.
GuastellaELongoRACarminaE. Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes. Fertil Steril. 2010;94(6):2197–2201.
28.
PanidisDTziomalosKMisichronisG. Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study. Hum Reprod. 2012;27(2):541–549.
29.
PioukaAFarmakiotisDKatsikisIMacutDGerouSPanidisD. Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Physiol Endocrinol Metab. 2009;296(2):E238–E243.
30.
DilbazBOzkayaECinarMCakirEDilbazS. Cardiovascular disease risk characteristics of the main polycystic ovary syndrome phenotypes. Endocrine. 2011;39(3):272–277.
31.
YilmazMIsaogluUDelibasIBKadanaliS. Anthropometric, clinical and laboratory comparison of four phenotypes of polycystic ovary syndrome based on Rotterdam criteria. J Obstet Gynaecol Res. 2011;37(8):1020–1026.
32.
KatsikisIKarkanakiAMisichronisGDelkosDKandarakiEAPanidisD. Phenotypic expression, body mass index and insulin resistance in relation to LH levels in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2011;156(2):181–185.
33.
Desforges-BulletVGalloCLefebvreCPignyPDewaillyDCatteau-JonardS. Increased anti-Mullerian hormone and decreased FSH levels in follicular fluid obtained in women with polycystic ovaries at the time of follicle puncture for in vitro fertilisation. Fertil Steril. 2010;94(1):198–204.
34.
KauffmanRPBakerTEBakerVMDiMarinoPCastracaneVD. Endocrine and metabolic differences among phenotypic expressions of polycystic ovary syndrome according to the 2003 Rotterdam consensus criteria. Am J Obstet Gynecol. 2008;198(6):670. e1–e7; discussion 670. e7–e10.
35.
BlankSKMcCartneyCRMarshallJC. The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome. Hum Reprod Update. 2006;12(4):351–361.
36.
SahmaySAtakulNOnculMTutenAAydoganBSeyisogluH. Serum anti-Mullerian hormone levels in the main phenotypes of polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2013;170(1):157–161.
37.
DewaillyDGronierHPonceletE. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod. 2011;26(11):3123–3129.
38.
PignyPJonardSRobertYDewaillyD. Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;91(3):941–945.
39.
LiYMaYChenX. Different diagnostic power of anti-Mullerian hormone in evaluating women with polycystic ovaries with and without hyperandrogenism. J Assist Reprod Genet. 2012;9(10):1147–1151.
40.
DewaillyDPignyPSoudanB. Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti-Müllerian hormone concentrations aggregate with the markers of hyperandrogenism. J Clin Endocrinol Metab. 2010;95(9):4399–4405.
41.
RosenfieldRLWroblewskiKPadmanabhanV. Antimüllerian hormone levels are independently related to ovarian hyperandrogenism and polycystic ovaries. Fertil Steril. 2012;98(1):242–249.
42.
PellattLHannaLBrincatM. Granulosa cell production of anti-Müllerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab. 2006;92(1):240–245.
43.
DewaillyDAndersenCYBalenA. The physiology and clinical utility of anti-Mullerian hormone in women. Hum Reprod Update. 2014;20(3):370–385.
